| Use of lipid conjugates in the treatment of infection -> Monitor Keywords |
|
|
  Use of lipid conjugates in the treatment of infectionUSPTO Application #: 20060189570Title: Use of lipid conjugates in the treatment of infection Abstract: This invention provides compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens. Also provided are compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating an infection in a subject. (end of abstract)
Agent: Pearl Cohen Zedek, LLP - New York, NY, US Inventor: Saul Yedgar USPTO Applicaton #: 20060189570 - Class: 514054000 (USPTO) Related Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), O-glycoside, Polysaccharide The Patent Description & Claims data below is from USPTO Patent Application 20060189570. Brief Patent Description - Full Patent Description - Patent Application Claims
CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation-in-part of U.S. application Ser. No. 10/952,496 filed Sep. 29, 2004, and a continuation-in-part of U.S. application Ser. No. 10/627,981, filed Jul. 28, 2003, which are continuation-in-part applications of U.S. application Ser. No. 09/756,765, filed Jan. 10, 2001, which claims priority from U.S. Provisional Application Ser. No. 60/174,905, filed Jan. 10, 2000, and U.S. Provisional Application Ser. No. 60/174,907 filed Jan. 10, 2000, which are hereby incorporated by reference. FIELD OF THE INVENTION [0002] This invention provides compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens. Also provided are compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating an infection in a subject. BACKGROUND OF THE INVENTION [0003] Lipid-conjugates are thought to inhibit the enzyme phospholipase A2 (PLA2, EC 3.1.1.4). Phospholipase A2 catalyzes the breakdown of phospholipids at the sn-2 position to produce a fatty acid and a lysophospholipid. The activity of this enzyme has been correlated with various cell functions, particularly with the production of lipid mediators such as eicosanoid production (prostaglandins, thromboxanes and leukotrienes), platelet activating factor and lysophospholipids. Lipid-conjugates may offer a wider scope of protection of cells and organisms from injurious agents and pathogenic processes, including the prevention and treatment of microbial infections. [0004] Microbial infections (e.g., infections by viral or bacterial species) account for significant morbidity and mortality throughout the world. Although significant resources have been dedicated to identifying compounds having antimicrobial properties, microbial infections continue to present a significant human health risk [0005] There are relatively few effective pharmaceutical compositions intended or adapted for antiviral, antifungal, or antiparasitic therapy. A major obstacle in the development of antiviral agents is the difficulty in distinguishing viral replicative mechanisms from host replicative processes. An additional limitation of existing antiviral drugs is that they have a narrow antiviral spectrum and are often ineffective against the latent virus. [0006] There are a much larger number of existing antibacterial agents, which has led to a significant decrease in morbidity and mortality from infectious diseases in this century. This important public health contribution has been largely due to the widespread use of antibiotics that target specific nutrient, cell wall, DNA, RNA and protein biosynthetic pathways that are particular to pathogenic bacteria. However, in recent years the capacity to manage infectious diseases has been threatened by the emergence of bacterial strains that are no longer susceptible to currently available antimicrobial agents. The widespread use of available antibacterial agents has led to the development of increasing numbers of antibiotic resistant bacteria. [0007] In fact, the usefulness of most existing antimicrobial treatments are limited by the development of multidrug resistance and the emergence of long-term toxicities. Other challenges include creating a drug that is broadly applicable in combating many different types of microbial infections, which is especially important in the treatment of immunocompromised individuals. SUMMARY OF THE INVENTION [0008] In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, comprising the step of contacting the cell with a compound comprising a lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. [0009] In another embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating an infection in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to an infected subject. BRIEF DESCRIPTION OF FIGURES [0010] FIG. 1.1: Effect of Lipid-conjugates on HIV infectivity. [0011] FIG. 2.1: Effect of Lipid-conjugates on injection of HeLa cells by Chlamydia. [0012] FIG. 2.2: Effect of Lipid-conjugates on Chlamydia-induced apoptosis of HeLa cells. [0013] FIG. 3.1: Inhibition of endothelin-1 (ET)-induced contraction of rat tracheal rings by Lipid-conjugates. A: Contraction of rat trachea by Endothelin-1. B: Effect of a Lipid-conjugate on ET-induced contraction of rat trachea, [0014] FIG. 3.2: Effect of Lipid-conjugates on ET-1 induced contraction of rat trachea. [0015] FIG. 3.3: Effect of Lipid-conjugates on Acetylcholine (AcCh)-induced contraction of isolated rat trachea rings. [0016] FIG. 3.4: Effect of a Lipid-conjugate, administered subcutaneously, on early asthmatic reaction (EAR) induced by ovalbumin (OVA) inhalation. [0017] FIG. 3.5: Effect of a Lipid-conjugate on sPLA.sub.2 expression in lung of rats with OVA-induced asthma. [0018] FIG. 3.6: Effect of a Lipid-conjugate on cysteinyl leukotriens (LTC.sub.4, LTD.sub.4 and LTE.sub.4) level in the broncho-alveolar lavage (BAL) of OVA-induced asthmatic rats. [0019] FIG. 3.7: Effect of Lipid-conjugate inhalation on early and late asthmatic reaction (EAR and LAR, respectively) in OVA-sensitized asthmatic rats. Continue reading... Full patent description for Use of lipid conjugates in the treatment of infection Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Use of lipid conjugates in the treatment of infection patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Use of lipid conjugates in the treatment of infection or other areas of interest. ### Previous Patent Application: Use of lipid conjugates in the treatment of infection Next Patent Application: Use of lipid conjugates in the treatment of infection Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Use of lipid conjugates in the treatment of infection patent info. IP-related news and info Results in 0.49909 seconds Other interesting Feshpatents.com categories: Medical: Surgery , Surgery(2) , Surgery(3) , Drug , Drug(2) , Prosthesis , Dentistry |
||
